Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02383043 · ClinicalTrials.gov registry record · Early Phase 1
Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer
A Early Phase 1 study, sponsored by Joshua A. Lile, Ph.D..
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT02383043: Completed Early Phase 1 study, sponsored by Joshua A. Lile, Ph.D..
NCT02383043 is a Early Phase 1 study that has completed, run by Joshua A. Lile, Ph.D.. The registered enrollment target is 18 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02383043, a Early Phase 1 study, has completed, sponsored by Joshua A. Lile, Ph.D..
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Cocaine-use disorders continue to be a significant public health concern, yet no effective medications have been identified. The goal of this study is to establish a research platform for the development of medications for treatment of cocaine abuse and dependence. This study will incorporate choice self-administration procedures between drug and a non-drug alternative reinforcer presented during maintenance on d-amphetamine, which has been previously shown to reduce cocaine use.
Primary Outcome
The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Lile et al., 2016) in which subjects made 9 choices between each available cocaine dose and money (US$6.00). Reinforcing effects are measured for each cocaine dose during both d-amphetamine and placebo maintenance.
Interventions
- DRUG Cocaine
- DRUG Sustained Release d-Amphetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-02-01 |
| Est. Completion | 2018-04-05 |
| Phase | Early Phase 1 |
What the finished NCT02383043 record still lists
NCT02383043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 2 interventions - of which Cocaine is the first listed.
NCT02383043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02383043 about?
NCT02383043 is a clinical study titled "Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer". Cocaine-use disorders continue to be a significant public health concern, yet no effective medications have been identified. The goal of this study is to establish a research platform for the development of medications for treatment of cocaine abuse and dependence. This study will incorporate choice...
What is the current status of trial NCT02383043?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2015-02-01. Estimated completion is 2018-04-05.
What interventions are being tested in trial NCT02383043?
The interventions under investigation include: Cocaine (DRUG), Sustained Release d-Amphetamine (DRUG).
Who is sponsoring clinical trial NCT02383043?
This trial is sponsored by Joshua A. Lile, Ph.D., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02383043's enrollment target sits among peer trials
18 1316th of 2000 higher than 651 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI